Guideline / position statementindependent cross-checkfull text checked★ key study I-ODD-16 in-depth review
ADA guideline 2026: diabetes medicines
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.
Overview
American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009
Insulin is essential in type 1 diabetes; SGLT2/GLP-1 drugs are recommended for heart and kidney protection; side effects listed.
Does the study support the specific claim? Partly · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Pharmacologic glycaemic treatment
- How was the study done?
Clinical practice guideline (ADA Standards of Care 2026, Section 9)
- How many people, animals or samples were studied?
not applicable; People with type 1 and type 2 diabetes
- What was actually found?
See results.
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
Medicines chosen by benefit-risk.
- What are the study's limitations?
Partially read
- What does it say about Elawady's specific claim?
Contradicts C-INS-07, C-INS-10, C-ODD-06; supports C-ODD-07, C-INS-11.
- Do the results apply to Germany and Europe?
Consistent with ADA/EASD consensus.
- What can explicitly not be concluded from this study?
Not applicable.
Scientific in-depth review
1. Full reference
- Authors
- American Diabetes Association Professional Practice Committee for Diabetes*
- Journal
- Diabetes Care
- Year
- 2026
- Identifier
- PMID 41358900 DOI 10.2337/dc26-S009
- Verification
- verified – PubMed efetch 2026-10-25 (this agent)
- Retracted
- no
- Corrections
- none
- Extent checked
- full text
- Conflicts of interest and funding
Duality of interest at doi 10.2337/dc26-SDIS.
2. Research question
Pharmacologic glycaemic treatment
3. Study design and population
- Study design
- Guideline / position statement – Clinical practice guideline (ADA Standards of Care 2026, Section 9)
- Population
People with type 1 and type 2 diabetes
- Country
USA (international use)
- Period
2026
- Sample size
not applicable
- Inclusion and exclusion criteria
As described in the abstract; details not available in abstract.
4. Methods and endpoints
- Exposure / intervention
not applicable
- Comparator
not applicable
- Endpoints
not applicable
- Statistical methods
Graded recommendations
5. Actual results
- Results
Full text (PMC12690185, read via PMC web page, first part): 'Insulin treatment is essential for individuals with type 1 diabetes' (Rec 9.1: most adults with T1D treated with insulin pump or MDI). Rec 9.7/9.8/9.10: medications with demonstrated CV benefit, SGLT2 inhibitor for HF, SGLT2 or GLP-1 RA for CKD, independent of A1C. Metformin associated with B12 deficiency; periodic testing suggested. Rec 9.20: consider insulin when symptomatic or A1C >10% / glucose >=300 mg/dL, especially with catabolic features. Table 9.2: GLP-1 RA - monitor for NAION; pancreatitis reported, causality not established; SGLT2 - Fournier gangrene rare, DKA risk with insulin deficiency.
- Absolute risks
not reported
- Authors' conclusion
Individualised, cardiorenal-protective pharmacotherapy; insulin essential in T1D.
6. Strengths
- Evidence-graded
7. Weaknesses
- Partially read
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
Guideline.
9. Assessment of the statistical interpretation
not applicable
10. Relevance to the specific claim
Contradicts C-INS-07, C-INS-10, C-ODD-06; supports C-ODD-07, C-INS-11.
11. Independent contrary findings
12. Transferability to Germany and Europe
Consistent with ADA/EASD consensus.
13. Overall methodological judgement
Current standard.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | low |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
None beyond those stated.
15. Linked fact checks
- There is no such thing as type 1 diabetes; 'type 1' is a state of high sugar seen mainly in athletes with high needs; type 1 patients do not develop complications; insulin before puberty is a catastrophe (short stature, thyroid problems, cysts). – Studies contradicting or limiting the claim
- People with diabetes can stop insulin and diabetes medication by following the Tayebat system ('zero medicine'), as shown by followers who stopped insulin and are 'perfectly fine'. – Studies contradicting or limiting the claim
- Archive conclusion: insulin is indispensable in type 1 diabetes; in type 2 diabetes, evidence supports caution with intensive dosing, prioritising metformin, weight loss and dietary change before insulin escalation, and aiming for moderate rather than near-normal HbA1c; this is not the same as rejecting insulin. – Studies supporting the claim
- Injectable diabetes and weight-loss drugs (GLP-1 receptor agonists) can trigger pancreatitis and cysts. – Studies with mixed or unclear results
- Long-term metformin lowers vitamin B12 and increases B12 deficiency (de Jager RCT: -19%, +7.2 percentage points deficiency over 4.3 years; DPPOS confirms). – Studies supporting the claim
- SGLT2 inhibitors are associated with Fournier gangrene: the FDA identified 55 cases in six years versus only 19 with all other diabetes drugs over 35 years. – Studies supporting the claim
- Semaglutide (Ozempic) is associated with a markedly higher risk of non-arteritic anterior ischaemic optic neuropathy (NAION), which can cause blindness (HR 4.28 in diabetes). – Studies supporting the claim
- Diabetes can be cured by following the Tayebat system without medication, illustrated by a patient who stopped insulin after 30 years of insulin use. – Studies contradicting or limiting the claim